Nektar guts workforce, weeks after $3.6B Bristol Myers immuno-oncology collaboration ends

Nektar guts workforce, weeks after $3.6B Bristol Myers immuno-oncology collaboration ends

Source: 
Fierce Biotech
snippet: 

Nektar is axing 70% of its staff and bidding adieu to top brass amid a strategic reorganization following the decay of the company’s once-historic collaboration with Bristol Meyer Squibb.